Position in GERN
as of Jun 30, 2026
· filed Jul 8, 2026
Position Value
$1,281,164
+$690,183 QoQ
Shares Held
1,000,910
+152.4% QoQ
Ownership
0.156%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#46
of 258 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GERN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Hennion & Walsh Asset Management, Inc. holds $200,308,891 across 60 Biotechnology names. GERN ranks #46 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JAZZ |
Jazz Pharmaceuticals plc
|
48,019 | $11,571,138 | |
| 2 | CELC |
Celcuity Inc.
|
100,368 | $10,500,500 | |
| 3 | URGN |
UroGen Pharma Ltd.
|
276,696 | $10,182,412 | |
| 4 | TVTX |
Travere Therapeutics, Inc.
|
171,470 | $9,741,210 | |
| 5 | SNDX |
Syndax Pharmaceuticals Inc
|
342,883 | $7,495,422 | |
| 6 | QURE |
uniQure N.V.
|
142,113 | $6,545,724 | |
| 7 | KURA |
Kura Oncology, Inc.
|
568,845 | $6,240,229 | |
| 8 | ARDX |
Ardelyx, Inc.
|
1,211,690 | $6,179,619 |
All Filings in GERN
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,281,164 | 1,000,910 | Shares | Sole | 2026-07-08 | |
| 2026-03-31 | $590,981 | 396,632 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $556,324 | 421,458 | Shares | Sole | 2026-01-14 | |
| 2025-09-30 | $499,228 | 364,400 | Shares | Sole | 2025-10-22 | |
| 2025-06-30 | $523,159 | 371,035 | Shares | Sole | 2025-08-07 | |
| 2025-03-31 | $617,199 | 388,176 | Shares | Sole | 2025-04-10 | |
| 2024-12-31 | $1,429,108 | 403,703 | Shares | Sole | 2025-01-15 | |
| 2024-09-30 | $1,552,153 | 341,884 | Shares | Sole | 2024-10-22 | |
| 2024-06-30 | $1,076,353 | 253,857 | Shares | Sole | 2024-07-19 | |
| No filing history on record for this holder in this stock. | ||||||